Bronnen:
- Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372:311-9.,Armand P, Shipp MA, Ribrag V, et al. Blockade with pembrolizumab in patients with classical Hodgkin’s lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;132:3733-9.,Casasnovas O, Brice P, Bouabdallah R, et al. Randomized phase III study comparing an early PET driven treatment de-escalationto a not PET-monitoring strategy in patients with advanced stages Hodgkin lymphoma: interim analysis of the AHL2011 Lysa study [abstract]. Blood. 2015; 126: abstr 577.,Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016;374:2419-29.,Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372:1598-607.,Andre MPE, Girinsky T, Federico M, et al. Early positron emission tomography-adapted treatment in stage I and II Hodgkin’s lymphoma: final results of the randomized EORTC/LYSA/FIL H10 study. J Clin Oncol. 2017;35:1786-94.,Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med. 2010;365:203-12.,Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183-9.,Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853-62.,LaCasce AS, Bociek G, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active salvage regimen for patients with relapsed or refractory Hodgkin Lymphoma. Blood. 2018; 132: 40-8.,Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or ABV for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14:1348-56.,Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. New Engl J Med. 2018;378:331-44.